Physician profile
Max W Berry
NPI 1578763355
$786.50
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $160 · 2021: $216 · 2022: $24.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $211.00 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $94.83 | 2019-2022 | |
| Medtronic Vascular, INC. | $88.06 | 2019-2020 | |
| Ekos Corporation | $84.07 | 2019 | |
| Biotronik INC. | $78.75 | 2019-2020 | |
| Terumo Medical Corporation | $65.63 | 2020 | |
| Boston Scientific Corporation | $47.39 | 2019-2020 | |
| Philips North America LLC | $45.91 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.59 | 2021 | |
| Medtronic, INC. | $14.30 | 2021 | |
| Pfizer INC. | $13.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.